Rekombinanter DLL3 (Rovalpituzumab Biosimilar) Antikörper

Produktnummer ABIN7795146

Der Humanized Monoklonal Anti-DLL3 (Rovalpituzumab Biosimilar) Antikörper wurde für FACS und in vivo validiert. Er ist geeignet, DLL3 (Rovalpituzumab Biosimilar) in Proben von Human zu detektieren.

Kurzübersicht für Rekombinanter DLL3 (Rovalpituzumab Biosimilar) Antikörper (ABIN7795146)

Target: DLL3 (Rovalpituzumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Humanized

Klonalität: Monoklonal

Konjugat: Dieser DLL3 (Rovalpituzumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-DLL3 (Rovalpituzumab Biosimilar) Antikörper

Expressionssystem: Mammalian cells

Verwendungszweck: Rovalpituzumab Biosimilar, Human DLL3 Monoclonal Antibody

Produktmerkmale: What is rovalpituzumab biosimilar research grade? Rovalpituzumab is a humanized IgG1-kappa monoclonal antibody against the human Delta-like 3 protein (DLL3), which is an atypical Notch ligand that has been implicated in regulation of cell development and cell fate decisions, and is a downstream target of achaetescute homolog-1 (ASCL1), suggesting its role in neuroendocrine tumorigenesis. DLL3 is expressed in more than 80 % of patients with small-cell lung cancer (SCLC) and other neuroendocrine tumors, but has little to no expression in normal tissues or non-neuroendocrine tumor types. DLL3 expression appears to be stable over time in SCLC tumors pre- and post-chemotherapy. Although DLL3 is mostly found within the Golgi apparatus under physiological conditions, it may reach the cell surface in case of overexpression and lead to Notch inhibition in cis. Rovalpituzumab tesirine (Rova-T) is a first-in-class antibody-drug conjugate (ADC) against DLL3, and composed of SC16, a humanized IgG1 antibody against DLL3, conjugated to the cytotoxic pyrrolobenzodiazepine (PBD) dimer D6.5 (SC-DR002) via a protease-cleavable linker. Rova-T selectively binds to DLL3 on target-expressing cells, is internalized, and upon proteolytic cleavage releases the toxin. PBD dimers then bind to the DNA minor groove where they form covalent adducts causing stalling of the replication forks, cell-cycle arrest at the G2-M boundary, and apoptosis. Rovalpituzumab biosimilar uses the same protein sequences as the therapeutic antibody rovalpituzumab.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human DLL3

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Details zu DLL3 (Rovalpituzumab Biosimilar)

Target: DLL3 (Rovalpituzumab Biosimilar)

Andere Bezeichnung: Rovalpituzumab Biosimilar

Substanzklasse: Biosimilar